Arcadia Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
RKDA$0.16-3.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
Exhibit Index
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber · Exhibit Description · Form · File No. · Exhibit · FilingDate · FiledHerewith | |||||
| 2.1 | Agreement and Plan of Exchange, by and among Arcadia Biosciences, Inc., and Roosevelt Resources LP, Elliott Roosevelt, Jr. and David A. Roosevelt, as Representatives of the Limited Partners, dated as of December 4, 2024. | 8-K | 001-37383 | 2.1 | 12/06/2024 |
| 3.1 | Amended and Restated Certificate of Incorporation of Registrant. | 8-K | 001-37383 | 3.1 | 5/26/2015 |
| 3.2 | Amendment to the Amended and Restated Certificate of Incorporation of Registrant. | 8-K | 001-37383 | 3.1 | 2/28/2023 |
| 3.3 | Certificate of Designation of Series A Preferred Stock. | 8-K | 001-37383 | 3.1 | 12/8/2022 |
| 3.4 | Amended and Restated Bylaws of Registrant. | 8-K | 001-37383 | 3.2 | 5/26/2015 |
| 3.5 | Amendment to the Amended and Restated Bylaws of Registrant. | 8-K | 001-37383 | 3.2 | 12/8/2022 |
| 4.1 | Form of Registrant’s common stock certificate. | S-3 | 333-224061 | 4.1 | 3/30/2018 |
| 4.2 | Form of Common Stock Purchase Warrant. | 8-K | 001-37383 | 4.1 | 3/23/2018 |
| 4.3 | Form of Common Stock Purchase Warrant. | 8-K | 001-37383 | 4.1 | 6/14/2019 |
| 4.4 | Form of Placement Agent Warrant. | 8-K | 001-37383 | 4.2 | 6/14/2019 | |
| 4.5 | Form of Common Stock Purchase Warrant. | 8-K | 001-37383 | 4.1 | 9/9/2019 | |
| 4.6 | Form of Placement Agent Warrant. | 8-K | 001-37383 | 4.2 | 9/9/2019 | |
| 4.7 | Description of Registrant’s Securities Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. | X | ||||
| 4.8 | Form of Common Stock Purchase Warrant. | 8-K | 001-37383 | 4.1 | 5/18/2020 | |
| 4.9 | Form of Placement Agent Warrant. | 8-K | 001-37383 | 4.2 | 5/18/2020 | |
| 4.10 | Form of Common Stock Purchase Warrant. | 8-K | 001-37383 | 4.1 | 7/8/2020 | |
| 4.11 | Form of Placement Agent Warrant. | 8-K | 001-37383 | 4.2 | 7/8/2020 | |
| 4.12 | Form of Investor Warrant. | 8-K | 001-37383 | 4.1 | 12/22/2020 | |
| 4.13 | Form of Placement Agent Warrant. | 8-K | 001-37383 | 4.2 | 12/22/2020 | |
| 4.14 | Form of Investor Warrant. | 8-K | 001-37383 | 4.1 | 1/29/2021 | |
| 4.15 | Form of Placement Agent Warrant. | 8-K | 001-37383 | 4.2 | 1/29/2021 | |
| 4.16 | Form of Investor Pre-Funded Warrant. | 8-K | 001-37383 | 4.1 | 8/16/2022 | |
| 4.17 | Form of Investor Preferred Investment Option. | 8-K | 001-37383 | 4.2 | 8/16/2022 | |
| 4.18 | Form of Placement Agent Preferred Investment Option. | 8-K | 001-37383 | 4.3 | 8/16/2022 | |
| 4.19 | Form of Pre-Funded Warrant. | 8-K | 001-37383 | 4.1 | 3/3/2023 | |
| 4.20 | Form of Series A Preferred Investment Option. | 8-K | 001-37383 | 4.2 | 3/3/2023 | |
| 4.21 | Form of Series B Preferred Investment Option. | 8-K | 001-37383 | 4.3 | 3/3/2023 | |
| 4.22 | Form of Placement Agent Preferred Investment Option. | 8-K | 001-37383 | 4.4 | 3/3/2023 | |
| 10.1* | Form of Indemnification Agreement between the Registrant and each of its Officers and Directors. | S-1 | 333-202124 | 10.7 | 2/17/2015 | |
| 10.2* | 2006 Stock Plan, as amended and restated, and form of agreement thereunder. | S-1 | 333-202124 | 10.8 | 2/17/2015 | |
| 10.3* | 2015 Omnibus Equity Incentive Plan and forms of agreement thereunder. | 10-Q | 001-37383 | 10.5 | 8/13/2024 | |
| 10.4* | 2015 Employee Stock Purchase Plan and form of agreement thereunder. | S-1/A | 333-202124 | 10.10 | 5/11/2015 | |
| 10.5* | Executive Incentive Bonus Plan. | S-1/A | 333-202124 | 10.15 | 5/11/2015 |
| 10.6* | Amended and Restated Director Compensation Policy. | 10-Q | 001-37383 | 10.14 | 5/10/2016 |
| 10.7* | Form of Severance and Change in Control Agreement. | S-1/A | 333-202124 | 10.18 | 4/6/2015 |
| 10.8 | Base Office Lease dated March 17, 2003 between the Registrant and Pac West Office Equities, LP, including Amendments 1-7. | S-1 | 333-229047 | 10.16 | 12/27/2018 |
| 10.9 | Amendment No. 8 to the Office Lease dated March 17, 2003 between the Registrant and Pac West Office Equities, LP. | 10-Q | 001-37383 | 10.8 | 5/13/2020 |
| 10.10 | Amendment No. 9 to the Office Lease dated March 17, 2003 between the Registrant and Pac West Office Equities, LP. | 10-Q | 001-37383 | 10.2 | 8/13/2020 |
| 10.11* | Employment Letter for Stanley E. Jacot Jr., Chief Executive Officer. | 10-Q | 001-37383 | 10.1 | 5/12/2022 |
| 10.12* | Severance and Change in Control Agreement for Stanley E. Jacot, Jr. | 10-Q | 001-37383 | 10.1 | 5/12/2022 |
| 10.13* | Inducement Option Grant for Stanley E. Jacot, Jr. | 10-Q | 001-37383 | 10.2 | 5/12/2022 |
| 10.14* | Employment Letter and Severance and Change in Control Agreement for Thomas J. Schaefer. | 8-K/A | 001-37383 | 10.1 | 1/5/2023 |
| 10.15+ | Limited Liability Company Operating Agreement for Archipelago Ventures Hawaii, LLC, dated as of August 9, 2019. | 8-K | 001-37383 | 10.1 | 8/9/2019 |
| 10.16 | Securities Purchase Agreement dated as of March 19, 2018, between Arcadia Biosciences, Inc. and each purchaser named in the signature pages thereto. | 8-K | 001-37383 | 10.1 | 3/23/2018 |
| 10.17 | Form of Registration Rights Agreement. | 8-K | 001-37383 | 10.2 | 3/23/2018 |
| 10.18 | Form of Securities Purchase Agreement dated as of June 11, 2018, between Arcadia Biosciences, Inc. and each purchaser named in the signature pages thereto. | 8-K | 001-37383 | 10.1 | 6/14/2018 |
| 10.19 | Form of Securities Purchase Agreement dated as of June 12, 2019, between Arcadia Biosciences, Inc. and each purchaser named in the signature pages thereto. | 8-K | 001-37383 | 10.1 | 6/14/2019 |
| 10.20 | Form of Securities Purchase Agreement dated as of September 5, 2019, between Arcadia Biosciences, Inc. and each purchaser named in the signature pages thereto. | 8-K | 001-37383 | 10.1 | 9/9/2019 |
| 10.21 | Form of Letter Agreement, dated as of May 14, 2020. | 8-K | 001-37383 | 10.1 | 5/18/2020 |
| 10.22 | Form of Letter Agreement, dated as of July 6, 2020. | 8-K | 001-37383 | 10.1 | 7/8/2020 |
| 10.23 | Form of Securities Purchase Agreement dated as of December 18, 2020, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. | 8-K | 001-37383 | 10.1 | 12/22/2020 |
| 10.24 | Form of Securities Purchase Agreement dated as of January 25, 2021, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. | 8-K | 001-37383 | 10.1 | 1/29/2021 |
| 10.25 | Form of Registration Rights Agreement dated as of January 25, 2021, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. | 8-K | 001-37383 | 10.2 | 1/29/2021 |
| 10.26 | Form of Securities Purchase Agreement, dated as of August 12, 2022, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. | 8-K | 001-37383 | 10.1 | 8/16/2022 |
| 10.27 | Form of Securities Purchase Agreement dated as of March 2, 2023, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. | 8-K | 001-37383 | 10.1 | 3/3/2023 |
| 10.28 | Form of Registration Rights Agreement dated as of March 2, 2023, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. | 8-K | 001-37383 | 10.2 | 3/3/2023 |
| 10.29 | Form of Investment Option Amendment, dated as of March 2, 2023. | 8-K | 001-37383 | 10.3 | 3/3/2023 |
| 10.30+ | Master Transaction Agreement. | 8-K | 001-37383 | 10.2 | 12/22/2020 |
| 10.31+ | Asset Purchase Agreement dated May 17, 2021, by and among Arcadia, Buyer, Seller, Eko, Lief, Zola and Parent. | 8-K | 001-37383 | 10.1 | 5/21/2021 |
| 10.32+± | Asset Purchase Agreement | 8-K | 001-37383 | 10.1 | 5/17/2024 |
| 10.33+± | Asset Purchase Agreement | 8-K | 001-37383 | 10.1 | 5/20/2024 |
| 10.34 | Promissory Note | 8-K | 001-37383 | 10.2 | 5/20/2024 |
| 10.35 | Security Agreement | 8-K | 001-37383 | 10.3 | 5/20/2024 |
| 10.36 | Employment Letter and Severance and Change in Control Agreement for Thomas J. Schaefer | 8-K/A | 001-37383 | 10.1 | 8/23/2024 |
| 10.37 | Employment Letter and Severance and Change in Control Agreement for Mark Kawakami | 8-K/A | 001-37383 | 10.2 | 8/23/2024 | |
| 21.1 | List of subsidiaries of the Registrant. | S-1 | 333-262407 | 21.1 | 1/28/2022 | |
| 23.1 | Consent of Deloitte & Touche LLP, independent registered public accounting firm. | X | ||||
| 24.1 | Power of attorney (included in the signature page to this filing). | X | ||||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 32.1 | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 32.2 | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 97.1 | Dodd-Frank Clawback Policy. | 10-K | 001-37383 | 97.1 | 3/28/2024 | |
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | X | ||||
| 104.1 | Cover page from the Company's Annual Report on Form 10-K for the year ended December 31, 2024, formatted in inline XBRL (and contained in Exhibit 101) | X | ||||
- Indicates a management contract or compensatory plan or arrangement.
- Certain information has been excluded from this exhibit because it is not material and would likely cause competitive harm to the registrant if publicly disclosed.
± Annexes, schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The registrant hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.